Reuben P Syiem*, Debastuti Bharali, Shikha Verma, Julie B Wahlang and Dhriti Kr Brahma

Department of Clinical Case Reports, India

*Corresponding Author: Reuben Process Syiem, Department of Clinical Case Reports, India.

Received: June 03, 2024; Published: June 25, 2024

Abstract

This case report describes a rare but serious adverse drug reaction – Steven Johnson Syndrome (SJS) induced by Carbamazepine. A female patient, aged 15, arrived at the Casualty unit complaining of redness and pain in both eyes, a painful lesion over her mouth, and a dusky red discoloration that had been present for six days throughout her face, neck, trunk, and upper limbs. The patient has a history of mental disorders, including temper tantrums, for which she was under medication. For the same initial diagnosis, she was administered a once-daily dose of carbamazepine and she received the medication for about four weeks. Nevertheless, the patient was brought to the Casualty unit four weeks after starting carbamazepine due to the aforementioned concerns. The patient was diagnosed with Carbamazepine-induced SJS and promptly treated with supportive measures followed by discontinuation of the offending drug.

Keywords: Carbamazepine; Stevens-Johnson Syndrome; Severe Cutaneous Reaction; Hypersensitivity Reactions; Adverse Drug Reactions

References

1. Auquier-Dunant A., et al. “Correlations between clinical patterns and causes of erythema multiforme majus, StevensJohnson syndrome, and toxic epidermal necrolysis: results of an international prospective study”. Archives of Dermatology 138 (2002): 1019-1024.
2. Mockenhaupt M., et al. “Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics”. Neurology 64 (2005): 1134-1138.
3. Devi K., et al. “Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years”. Indian Journal of Dermatology, Venereology and Leprology 71 (2005): 325-328.
4. Grimsley SR., et al. “Increased carbamazepine plasma concentrations after fuoxetine coadministration”. Clinical Pharmacology and Therapeutics 1 (1991): 10-15.
5. Mockenhaupt M., et al. “Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphon recently marketed drugs. The Euro SCAR-study”. Journal of Investigation Dermatology1 (2008): 35-44.

Citation

Citation: Reuben Process Syiem., et al. “Rare but Severe: A Case Report of Carbamazepine-Induced Stevens-Johnson Syndrome".Acta Scientific Clinical Case Reports 5.7 (2024): 63-65.

Copyright

Copyright: © 2024 Reuben Process Syiem., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.